ACM
AUPH icon

Andina Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Andina Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,851
Closed -$398K – 76
2026
Q1 		$398K Buy
+26,851
New +$392K 0.35% 66

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
NFG
Norris Financial Group Greenville, South Carolina $251M AUM 48.4% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Andina Capital Management's AUPH Position: Q2 2026 in Review

Andina Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 26,851 shares — an estimated $398K sold.

Andina Capital Management first reported a position in AUPH in Q1 2026 and held it in 1 quarter. The position peaked at $398K in Q1 2026. 124 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Andina Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Andina Capital Management sold 26,851 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $398K.
  • Andina Capital Management first reported a position in Aurinia Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Andina Capital Management's Aurinia Pharmaceuticals position peaked at $398K in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Andina Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.